|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2000 GALLOPING HILL ROAD |
Address2 |
|
City | KENILWORTH |
State | NJ |
Zip Code | 07003 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 24908-12
|
||||||||
|
6. House ID# 313040000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Corey Malmgren |
Date | 10/20/2020 1:41:58 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing
H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act
H.R. 2296, More Efficient Tools to Realize Information for Consumers Act
H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance
H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019
H.R. 4629, Star Rating for Biosimilars Act
H.R. 5076, Protecting Seniors Through Immunization Act of 2019
H.R. 6197, Increasing Access to Biosimilars Act of 2020
H.R. 8061, Community Immunity During COVID-19 Act of 2020
S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act
S. 1895, Lower Health Care Costs Act
S. 2543, Prescription Drug Pricing Reduction Act of 2019
Issues relating to,
340B Reforms;
340B program integrity;
340B of the Public Health Services Act;
Drug pricing;
Anti-microbial Resistance;
General Pharmaceutical issues transparency, formulary design, prescription drug coverage;
Biosimiliars;
Cost and value of medicines;
Maternal Health;
Vaccines;
Adult vaccines and immunizations;
Supply chain;
Coronavirus stimulus funding;
HIV;
Rebate pass through;
COVID-19 vaccines;
Vaccines catch up;
Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014);
Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Liz |
Schwartz |
|
|
|
Erin |
Darling |
|
|
|
Corey |
Malmgren |
|
|
|
Bob |
Filippone |
|
|
|
Adam |
Huftalen |
|
Staff Associate, House Foreign Relations Committee/Rep. Tom Lantos, March 2007 - May 2008 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate
Issues relating to,
Medicaid;
Medicare;
Medicare Part B;
340B reforms;
340B program integrity;
340B of the Public Health Services Act;
Medicare Part D;
Drug Pricing;
Center for Medicare and Medicaid demonstrations;
Part D inflationary rebate;
International pricing reference.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Bob |
Filippone |
|
|
|
Liz |
Schwartz |
|
|
|
Corey |
Malmgren |
|
|
|
Erin |
Darling |
|
|
|
Adam |
Huftalen |
|
Staff Associate, House Foreign Relations Committee/Rep. Tom Lantos, March 2007 - May 2008 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to,
Tax Reform, Generally;
Tax Cuts and Jobs Act of 2017 (P.L. 115-97)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Adam |
Huftalen |
|
Staff Associate, House Foreign Relations Committee/Rep. Tom Lantos, March 2007 - May 2008 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Issues relating to,
Intellectual Property;
US-Mexico-Canada Agreement.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Liz |
Schwartz |
|
|
|
Bob |
Filippone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |